As the CEO and co-founder of Intelligencia AI™, Dimitrios Skaltsas leads the AI-driven technology organization's business and investment growth strategy while overseeing critical functional areas of the multidisciplinary global team. Founded in 2017, Intelligencia AI leads the way in leveraging proprietary data, biomedical expertise and artificial intelligence (AI) with its patented technology to address significant challenges in the pharmaceutical industry. These challenges include lengthy drug development timelines, excessive costs, and unsustainable return on investment (ROI). Its suite of AI-powered solutions delivers actionable insights crucial in mitigating risks and enhancing decision-making associated with drug development by providing an accurate, unbiased assessment of a drug’s probability of success.
In 2024, the company received a U.S. patent for its accurate and transparent probability of drug success assessments. It also earned its inaugural spots on the Inc. Regional (Northeast) and Inc. 5000 for the first time. The Healthcare Technology Report recognized it as one of the Top 100 Healthcare Technology Companies. In 2021, the company completed its Series A funding and was named one of Forbes's Top AI Companies to Watch. During this time, Dimitrios played an instrumental role in forging a strategic partnership with ZS, a global professional services company. Before tapping into his entrepreneurial spirit and co-founding Intelligencia AI, Dimitrios spent over a decade in various leadership roles within the healthcare and life sciences sectors.
He holds an MBA from INSEAD and a law degree from University College London (UCL) and the University of Athens. In his leisure time, you can find him painting or enjoying the Greek countryside.